MedTrace Logo

Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial

NCT05639959 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-12-07

No results posted yet for this study

Summary

Seasonal and perennial allergic rhinitis, acute rhino sinusitis, and nasal polyposis are examples of common inflammatory disorders of the airway that significantly reduce patient health and quality of life. Intranasal corticosteroids are advised as part of treatment plans for each of these illnesses since they help to reduce inflammation and thus symptoms.

Objective In order to assess the effectiveness and safety of a new nano formulation of Mometasone furoate nano-nasal spray (FM-NNS) for the treatment of allergic rhinitis. Mometasone Furoate Nano-nasal spray (FM-NNS) was compared with commercial available nasal spray named as MFNS.

Conditions

  • Acute Rhinosinusitis

Interventions

DRUG

Mometasone Nasal 50 Mcg/Inh Nasal Spray

Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.

DEVICE

Nasal spray

device can work properly for actuation during trials

Sponsors & Collaborators

  • Saffron Pharma

    lead INDUSTRY

Eligibility

Min Age
10 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-10
Primary Completion
2022-11-06
Completion
2022-11-06
FDA Drug
Yes
FDA Device
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05639959 on ClinicalTrials.gov